5 Stocks to Watch: Week of 3/2/2025
Happy March. Let’s roar into this month with a curated list of 5 stocks with high upside potential and excellent fundamentals. We’ve got:
- The whole “buy the plunge” thing with Semtech Corp (NASDAQ: SMTC)
- Analysts are almost unanimously bullish on GE Healthcare Technologies Inc (NASDAQ: GEHC)
- What made Wix.com Ltd (NASDAQ: WIX) earn Stock of the Week status
- Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) has surprisingly good financials for a biotech
- A top-rated analyst just raised their price target on HubSpot Inc (NYSE: HUBS) by $100
P.S. Did you miss last week's picks? Click here.
1- Jazz Pharmaceuticals PLC (NASDAQ: JAZZ)
You might think that this is yet another ambitious, risky biotech startup — and you’d be wrong, Jazz Pharmaceuticals has been in business for 22 years — and maintains a portfolio of leading treatments in neurology, oncology, and several rare medical issues. At present, JAZZ stock represents a very rare blend of growth and value — one that merits closer consideration.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $143.27 — get current quote >
Max 1-year forecast: $210.00
Why we’re watching:
- Wall Street is unequivocally bullish on JAZZ — a consensus Strong Buy, the stock carries 4 Strong Buy ratings and 4 Buy ratings. See the ratings
- Wells Fargo researcher Mohit Bansal (a top 14% rated analyst) upgraded the stock from a Buy to a Strong Buy on February 13, following the company’s Q4 and FY report released a day earlier. In addition, the researcher increased his price target for Jazz Pharmaceuticals stock from $130 to $170.
- Bansal attributed their upgrade and price target hike to the recent IP settlement on the $1B Epidiolex franchise. The analyst explained that the deal de-risks Jazz Pharmaceuticals' long-term financials.
- Further, Bansal told readers, Wells Fargo sees a "high probability of success" for Zanidatamab for first-line GEA (gastroesophageal adenocarcinoma) trial, calling it a "potentially transformative catalyst" with a read-out expected in Q2 of this year.
- With a Zen Rating of A, JAZZ falls in the top 5% of stocks tracked by our proprietary ranking model — and stocks of this caliber have historically outperformed the market since the turn of the millennium. If that wasn’t enough of an endorsement, JAZZ is actually rated in the top 1%, so it belongs to an even more exclusive group of stocks.
- One thing that immediately jumps out is a rare blend of valuation and growth — Jazz Pharmaceuticals is in the top 1% of all stocks in terms of its Value Component Grade rating, and in the top 5% in terms of its Growth Component rating. Simply put, this is quite the undervalued stock — especially relative to its growth potential (See all 7 Zen Component Grades here >)
2- Wix.com Ltd (NASDAQ: WIX)
Wix is a no-code, online platform that allows individuals and businesses to create and manage their own websites, e-commerce stores, and service providers. Cheap and abundant AI will supercharge Wix’s offerings related to building websites, payment processing, content creation, customer service, analytics, personalization, marketing, and automation.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $202.02 — get current quote >
Max 1-year forecast: $300.00
Why we’re watching:
- It’s our Stock of the Week — Zen Investor Editor-in-Chief Steve Reitmeister gave WIX stock a nod on Monday on account of promising growth metrics and a strong track record of outperforming earnings estimates. You can check out his article here. Here’s a closer look at his rationale:
- The business has managed to significantly increase its average revenue per user (ARPU). Moreover, it ranks in the top 4% of stocks when looking at Growth Component Grade scores, and the top 6% when looking at Financials.
- In addition, Wix.com has beat analyst estimates for earnings per share (EPS) by an average of 17% when looking at the last 4 quarters.
- Despite such promising data points, WIX shares are still trading some 19% off of a recent late-January high.
- Among the 16 equity researchers who track the stock and issue ratings for it, WIX is a consensus Strong Buy. As noted by our Editor-in-Chief, even the average 12-month price forecast of $251.56 implies a pretty significant 26.98% upside — and some of Wall Street’s top analysts are even more optimistic.
- Our Zen Ratings analysis, which takes into account 115 factors correlated with outsized returns, gives Wix.com stock an overall rating of A, placing it in the top 5% of the 4,600+ equities we track. In fact, it actually ranks in the top 2% — and as Steve put it, there are really no particular weaknesses at play here. (See all 7 Zen Component Grades here >)
- As a side note, WIX is a recent addition to our Zen Investor portfolio. Even with the recent dip, it’s up considerably:
3- HubSpot Inc (NYSE: HUBS)
In contrast with Freshworks, we have HubSpot — a large, well-established CRM and marketing automation business. With a subscription-based model that drives steady revenue growth and the ever-increasing popularity of automation tools, HubSpot is well-positioned to see further growth in the rest of 2025.
Zen Rating: B (Buy) — see full analysis >
Recent Price: $713.19 — get current quote >
Max 1-year forecast: $980.00
Why we’re watching:
- HubSpot has earned broad analyst support. Of the 23 analysts who track it, 12 deem it a Strong Buy, 7 rate it a Buy, and 4 rate it a Hold. See the ratings
- After the company’s Q4 and FY 2024 earnings report, JPMorgan’s Mark Murphy (a top 10% rated analyst) called Q4 "another quarter of differentiated performance”, reiterated a prior Strong Buy rating, and increased his price target for HUBS stock from $725 to $825.
- Looking ahead, the analyst told readers that JP Morgan continues to see "various positive vectors across the business."
- In addition, JP Morgan is encouraged by the potential for accelerating growth rates off what HubSpot management expects to be "a fiscal trough in Q1 2025."
- HubSpot stock carries an overall Zen Rating of B — placing it in the top 20% of stocks we track.
- HUBS shines for Growth, with an A rating, indicating a high potential for expanding margins, EPS growth, and sales acceleration. (See all 7 Zen Component Grades here >)
4- Semtech Corp (NASDAQ: SMTC)
Investors often come across the phrase “buy the dip” — but with Semtech Corp, it’d be more apt to say “buy the plunge.” After an unexpected setback when it comes to revenue from a crucial segment, SMTC stock has lost 38.25% in value since the beginning of the year. However, there’s an odd dissonance at play — while analysts have cut their price targets accordingly, they’re still bullish, and see plenty of upside — particularly at the current, reduced valuation.
Zen Rating: B (Buy) — see full analysis >
Recent Price: $35.06 — get current quote >
Max 1-year forecast: $85.00
Why we’re watching:
- In the interest of brevity, we won’t go into as much granular detail with SMTC. At present, despite the “plunge”, of the 11 researchers who issue ratings for the stock, 7 rate it a Strong Buy, and 4 rate it a Buy. We highly recommend taking a look at the ratings yourself
- To keep it short, since the beginning of February, 4 of Wall Street’s top equity analysts have maintained Buy or Strong Buy ratings. They are Craig Ellis of Baird, Needham’s Quinn Bolton, Harsh Kumar of Piper Sandler, and Tore Svanberg of Stifel Nicolaus.
- When we say top equity analysts, we mean it — the aforementioned are ranked in the top 1%, 1%, 2%, and 4% of Wall Street researchers, respectively.
- While all of the analysts we’ve mentioned have noted their disappointment with the company’s drop in active copper cable revenue below what the company earlier referred to as a ‘floor case’, once that was factored into their models, their price targets still reflect significant upside.
- Respectively, the analysts we’ve singled out see a 58.35%, 42.52%, 45.16%, and 84.75% upside for SMTC stock in the next 12 months.
- With an overall Zen Rating of B, SMTC ranks in the top 20% of the stocks we track.
- Unsurprisingly, the stock’s Growth Component Grade rating, an A, is the star of the show — in this category, it is ranked in the 98th percentile. (See all 7 Zen Component Grades here >)
5- GE Healthcare Technologies Inc (NASDAQ: GEHC)
Spun off of General Electric back in early 2023, our second entry is a business that provides medical imaging, diagnostics, and patient monitoring systems in hospitals and clinics in more than 160 countries across the world. The company’s latest earnings call was better than expected — and two eminent analysts recently gave GEHC their seal of approval.
Zen Rating: B (Buy) — see full analysis >
Recent Price: $89.40 — get current quote >
Max 1-year forecast: $110.00
Why we’re watching:
- GE Healthcare Technologies enjoys broad, nearly unanimous support from equity researchers. At present, 8 analysts track GEHC stock and issue ratings for it — 5 rate it a Strong Buy, while the rest of the ratings are evenly split between Buy, Hold, and Strong Sell — with 1 each. See the ratings
- Citigroup’s Joanne Wuensch (a top 6% rated analyst) reiterated an earlier Strong Buy rating on February 13, after the company released its Q4 and FY 2024 report. She raised her price target from $103 to $110.
- Earnings per share came in above estimates — while revenues missed forecasts by just 0.25%.
- Wuensch summarized the quarter thusly: Operating margins expanded "significantly." in Q4, driving EPS ahead of consensus, while total company organic order increased by 6% Y/Y — and an increase in book-to-bill ratio reflects continued product demand.
- Looking ahead, the analyst said management's FY 2025 guidance "seems conservative."
- Much of the same was echoed by Larry Biegelsen of Wells Fargo (a top 8% rated analyst), who also doubled down on a previous Strong Buy rating and increased his price target from $96 to $103.
- Regarding guidance, the analyst told readers that management expects headwinds in China to slow growth in that market in 1H 2025. Management also expects growth in China in 2H 2025, resulting in FY 2025 in the market to be down in the low single digits.
- GEHC carries an overall Zen Rating of B — among the top 20% of stocks we track.
- A particular highlight is the stock’s Safety Component Grade rating of A — in this category, Ge Healthcare ranks in the 99th percentile, indicating extremely consistent earnings and operational metrics. (See all 7 Zen Component Grades here >)
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.